NCT05172245
See how this trial matches your record
Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin, which is a chemotherapy used in this trial, is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib in combination with chemo-radiation may be better than chemo-radiation alone in treating patients with advanced head and neck cancer.
University Health Network-Princess Margaret Hospital
Toronto, Canada
Moffitt Cancer Center
Tampa, Florida
Site Public Contact · 800-679-0775 · ClinicalTrials@moffitt.org
Northwestern University
Chicago, Illinois
Site Public Contact · 312-695-1301 · cancer@northwestern.edu
University of Kansas Clinical Research Center
Fairway, Kansas
Site Public Contact · 913-588-3671 · KUCC_Navigation@kumc.edu
University of Kansas Cancer Center
Kansas City, Kansas
Site Public Contact · 913-588-3671 · KUCC_Navigation@kumc.edu